Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Lumos Pharma)"
Count: 38
Selected: 0
NCT05250063Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial
NCT04806854PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency.
NCT04614337Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
NCT05469490Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors
NCT03852446Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers
NCT03372239Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers
NCT03301636A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
NCT03165188Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy
NCT03164603NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
NCT02835729A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT02648711Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
NCT02502708Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
NCT02460367Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
NCT02405585Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
NCT02389985A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT02380677Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
NCT02187302CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
NCT02077881Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
NCT02073123Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
NCT02054520Immunotherapy Study for Patients With Stage IV Melanoma
NCT02052648Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
NCT02035358Immunotherapy Study for Metastatic Renal Cell Cancer
NCT01836432Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
NCT01792050Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
NCT01774578Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
NCT01380769A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
NCT01072981Immunotherapy Study for Surgically Resected Pancreatic Cancer
NCT00753740Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.
NCT00739609IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
NCT00614601Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
NCT00569387Vaccine Study for Surgically Resected Pancreatic Cancer
NCT00420732Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer
NCT00333502Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
NCT00300612Vaccine Treatment for Advanced Malignant Melanoma
NCT00255827Vaccine Treatment for Surgically Resected Pancreatic Cancer
NCT00105053Vaccine Treatment for Hormone Refractory Prostate Cancer
NCT00090480Vaccine Treatment for Advanced Breast Cancer
NCT00073398Vaccine Treatment for Advanced Non-Small Cell Lung Cancer